Restless Legs Syndrome (Willis-Ekbom Disease)

1. Clinical Overview

Definition and Significance

Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a common sensorimotor neurological disorder characterised by an irresistible urge to move the legs, usually accompanied by uncomfortable and unpleasant sensations deep in the legs. [1] This condition represents one of the most prevalent movement disorders affecting sleep, with significant impact on quality of life comparable to chronic medical conditions such as type 2 diabetes and clinical depression. [2]

The disorder was first comprehensively described by Karl-Axel Ekbom in 1945, though earlier descriptions exist dating back to the 17th century. The modern diagnostic criteria were established by the International Restless Legs Syndrome Study Group (IRLSSG) and revised in 2014 to improve specificity and reduce overdiagnosis. [1]

RLS is distinguished by four cardinal features: an urge to move the legs with or without uncomfortable sensations, symptom onset or worsening during rest or inactivity, partial or complete relief with movement, and circadian variation with symptoms worse in the evening and night. [1] These features form the cornerstone of clinical diagnosis in a condition where objective biomarkers remain elusive.

Key Facts

Clinical Pearls

• Ferritin Threshold is Critical: Standard laboratory "normal" ferritin (> 15 μg/L) is misleading in RLS. Brain iron deficiency can occur with ferritin 15-75 μg/L. Target ferritin > 75-100 μg/L with transferrin saturation > 20%. [4,7]

• Ask the Diagnostic Question: "Do you have uncomfortable sensations in your legs with an urge to move them that is worse when resting and better with movement, especially at night?" This captures the four essential criteria.

• Augmentation is the Great Treatment Complication: Long-term dopamine agonist use leads to augmentation (paradoxical worsening) in 20-60% of patients. [6] Recognise early: symptoms starting earlier in the day, spreading to arms, shorter medication relief.

• Medication Review is Essential: Many common medications exacerbate RLS including antihistamines (diphenhydramine), most antidepressants (SSRIs, SNRIs, TCAs, mirtazapine), antipsychotics, antiemetics (metoclopramide, prochlorperazine), and some anticonvulsants. [8]

• It's Not Just Insomnia: RLS causes profound quality of life impairment equal to major chronic diseases. Screen for depression, anxiety, and functional limitations. [2]

• Pregnancy is a High-Risk Period: Prevalence increases to 20-30% in pregnancy, especially third trimester, usually resolving within 1 month postpartum. [9]

---

2. Epidemiology

Prevalence and Demographics

Restless legs syndrome is one of the most common neurological disorders, though prevalence estimates vary depending on diagnostic criteria strictness and population studied.

Age Distribution

RLS demonstrates a bimodal age distribution:

Early Onset (Age less than 45 years):

• Often familial (> 60% positive family history) [3]
• More gradual progression
• Higher genetic burden
• Often begin in childhood or adolescence but may not seek care until adulthood
• Stronger association with periodic limb movements
• Better response to dopaminergic therapy (but higher augmentation risk)

Late Onset (Age > 45 years):

• More often sporadic
• Steeper symptom progression
• Higher association with comorbidities (cardiovascular disease, CKD)
• More likely to have secondary causes
• May represent different pathophysiology

Geographic and Ethnic Variation

Prevalence varies significantly by ethnicity:

• Highest: Northern European and North American populations (10-15%)
• Intermediate: Southern European populations (5-10%)
• Lower: East Asian populations (1-7%)
• Lowest: Sub-Saharan African populations (less than 3%)

This variation suggests genetic susceptibility differences across populations, supported by genome-wide association studies identifying risk variants more common in European ancestry. [3]

Risk Factors

Medication-Associated RLS

Many commonly prescribed medications can precipitate or exacerbate RLS: [8]

High Risk:

• Antidopaminergic antiemetics (metoclopramide, prochlorperazine)
• Typical antipsychotics (haloperidol, chlorpromazine)
• Atypical antipsychotics (risperidone, olanzapine, quetiapine)
• Sedating antihistamines (diphenhydramine, promethazine)

Moderate Risk:

• SSRIs (fluoxetine, sertraline, citalopram, escitalopram)
• SNRIs (venlafaxine, duloxetine)
• Tricyclic antidepressants (amitriptyline, imipramine)
• Mirtazapine
• Lithium

Lower Risk but Reported:

• Some beta-blockers
• Calcium channel blockers
• Some anticonvulsants (phenytoin)

---

3. Pathophysiology

The pathophysiology of RLS is complex and incompletely understood, involving iron dysregulation, dopaminergic dysfunction, genetic susceptibility, and circadian rhythm abnormalities.

Iron Hypothesis

Central to RLS pathophysiology is brain iron deficiency, which can occur despite normal or even elevated serum iron indices. [7]

Systemic Iron Deficiency (Ferritin less than 75 μg/L)
                ↓
Reduced Iron Transport Across Blood-Brain Barrier
                ↓
Brain Iron Deficiency (substantia nigra, putamen)
                ↓
Reduced Tyrosine Hydroxylase Activity
(rate-limiting enzyme requiring iron as cofactor)
                ↓
Decreased Dopamine Synthesis
                ↓
Dopaminergic Dysfunction in A11 Pathway
                ↓
RLS Symptoms

Key Evidence:

• CSF ferritin is reduced in RLS patients even with normal serum ferritin [7]
• MRI studies show decreased brain iron in substantia nigra and putamen
• Autopsy studies confirm reduced brain iron and reduced iron transporters
• Iron supplementation improves symptoms in iron-deficient patients [4]
• Severity correlates inversely with serum ferritin levels

Why the 75 μg/L Threshold?: Research demonstrates that brain iron deficiency can occur with serum ferritin 15-75 μg/L. While this is "normal" by general laboratory standards, it is insufficient for optimal brain iron homeostasis. Studies show symptomatic improvement when ferritin is increased to > 75-100 μg/L. [4,7]

Dopaminergic Hypothesis

RLS involves dopaminergic dysfunction in the diencephalospinal A11 pathway, which projects from the hypothalamus to the spinal cord. [11]

Paradox of Dopaminergic Dysfunction:

• RLS symptoms respond to dopamine agonists → suggests dopaminergic hypofunction
• BUT: RLS is NOT a dopamine deficiency state like Parkinson's disease
• CSF dopamine metabolites are normal or elevated
• Dopamine replacement is NOT curative and causes augmentation

Current Model:

• Central dopaminergic hyperactivity in some pathways
• Dopaminergic hypofunction in the A11 diencephalospinal tract
• Altered dopamine receptor sensitivity (D2/D3 receptors)
• Iron deficiency impairs dopamine synthesis and receptor function
• Circadian variation in dopamine activity (lowest at night)

Genetic Basis

RLS has a strong genetic component with 40-60% of cases reporting family history. [3]

Inheritance Pattern:

• Complex polygenic inheritance
• Autosomal dominant pattern in some families
• Earlier onset in familial cases

Identified Genetic Loci (from GWAS studies): [3] 19 genome-wide significant risk loci identified, including:

None of these genes have been definitively linked to dopamine or iron metabolism, suggesting RLS pathophysiology involves additional unknown mechanisms.

Circadian Variation

The hallmark worsening of symptoms in evening/night is related to circadian factors: [11]

• Dopamine levels: Show circadian variation (lowest at night)
• Iron regulation: Fluctuates with circadian rhythm
• Core body temperature: Symptoms worsen with increased temperature
• Cortisol: Decreased cortisol at night may reduce dopaminergic tone
• Hypocretin/orexin: Wakefulness-promoting systems affect RLS

Adenosine Hypothesis

Emerging evidence suggests adenosine system involvement:

• Adenosine A1 receptor dysfunction may contribute
• Adenosine modulates dopaminergic activity
• May explain why some caffeine-containing medications worsen RLS

Secondary RLS: Specific Mechanisms

---

4. Clinical Presentation

Diagnostic Criteria

The International RLS Study Group (IRLSSG) 2014 Updated Diagnostic Criteria require ALL five essential criteria: [1]

Essential Criteria (all must be present):

1. Urge to move the legs, usually but not always accompanied by, or felt to be caused by, uncomfortable and unpleasant sensations in the legs

2. Urge to move the legs and any accompanying unpleasant sensations begin or worsen during periods of rest or inactivity such as lying down or sitting

3. Urge to move the legs and any accompanying unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues

4. Urge to move the legs and any accompanying unpleasant sensations during rest or inactivity only occur or are worse in the evening or night than during the day

5. Occurrence of the above features is not solely accounted for as symptoms primary to another medical or behavioural condition (e.g., myalgia, venous stasis, leg oedema, arthritis, leg cramps, positional discomfort, habitual foot tapping)

Specifiers:

• Chronic-persistent RLS: Symptoms when not treated would occur on average at least twice weekly for the past year
• Intermittent RLS: Symptoms when not treated would occur on average less than 2 times per week for the past year, but at least 5 lifetime events
• Clinically significant RLS: Symptoms cause distress or impairment in functioning

Symptom Descriptions

Patients use vivid and varied descriptions for the leg sensations. Clinicians should ask patients to describe the sensation in their own words:

Important Clinical Points:

• Sensations are usually bilateral (70-80%) but can be unilateral
• Primarily affect calves and thighs, but can involve feet, arms (20%), trunk (rare)
• Described as deep sensations, not superficial or cutaneous
• Difficult for patients to describe precisely
• Urge to move may occur without dysesthesia (particularly in children)

Symptom Timing and Triggers

Associated Features

Periodic Limb Movements (PLMs)

• Present in 80-90% of RLS patients during polysomnography [12]
• Brief (0.5-10 second) repetitive limb movements during sleep
• Stereotyped extension of big toe, dorsiflexion of ankle, flexion of knee/hip
• Occur every 20-40 seconds in periodic clusters
• NOT diagnostic of RLS (occur in many conditions and normal elderly)
• CAN occur without RLS (isolated periodic limb movement disorder)

Sleep Disturbance

Psychological and Quality of Life Impact

RLS has profound impact on quality of life comparable to other chronic diseases: [2]

• Depression: 2-3 times higher prevalence than general population
• Anxiety: Significantly increased
• Cognitive impairment: From chronic sleep deprivation
• Work impairment: Presenteeism, difficulty with sedentary work
• Social limitations: Avoiding cinema, theatre, long car journeys
• Relationship impact: Partner sleep disturbance, intimacy affected

Symptom Severity Assessment

The International RLS Severity Scale (IRLS) is a validated 10-item questionnaire:

Paediatric Considerations

RLS in children is often underdiagnosed:

Diagnostic Challenges:

• Younger children may not articulate symptoms well
• Often misdiagnosed as "growing pains"
• May present as bedtime resistance or behavioural problems
• Supportive criteria: sleep disturbances, family history, periodic limb movements

Modified Paediatric Criteria:

• Same 5 essential criteria as adults, BUT
• Child describes symptoms in own words, OR
• Two of: sleep disturbance, biological parent/sibling with RLS, polysomnography-documented periodic limb movements (≥5 per hour)

---

5. Clinical Examination

General Principles

RLS is a clinical diagnosis based on history. Physical examination is typically normal in primary RLS but is essential to identify secondary causes and exclude mimics.

Systematic Examination Approach

Key Examination Findings by Cause

What NOT to Expect in Primary RLS

The following findings should prompt investigation for alternative or comorbid diagnoses:

• ❌ Objective sensory deficits
• ❌ Motor weakness
• ❌ Muscle wasting or atrophy
• ❌ Pathological reflexes
• ❌ Visible leg abnormalities
• ❌ Reproducible tender points

---

6. Differential Diagnosis

RLS must be distinguished from other conditions causing leg discomfort or movement. The 5th diagnostic criterion specifically requires excluding other primary causes.

Key Differentials

"RLS Mimics"

• Conditions Often Confused with RLS

Conditions That May Coexist with RLS

Some conditions commonly occur alongside RLS:

• Iron deficiency anaemia
• Periodic limb movement disorder (in 80-90% of RLS) [12]
• Sleep apnoea (common comorbidity)
• Depression and anxiety (consequence and possibly shared pathophysiology)
• Migraine (possible shared genetics)
• Small-fibre neuropathy

---

7. Investigations

Diagnostic Approach

RLS is a clinical diagnosis. There is no definitive diagnostic test. Investigations serve to:

1. Identify secondary causes (especially iron deficiency)
2. Exclude differential diagnoses
3. Assess comorbidities
4. Provide baseline for treatment monitoring

First-Line Investigations (All RLS Patients)

Second-Line Investigations (Selected Patients)

Polysomnography Findings

While not required for diagnosis, polysomnography can provide supportive evidence:

Periodic Limb Movements (PLMs):

• ≥15 PLMs per hour in adults (≥5/hour in children) supports RLS diagnosis [12]
• Present in 80-90% of RLS patients
• NOT specific (occur in other conditions and 30% of elderly)
• Characterised by:
  • "Duration: 0.5-10 seconds"
  • "Interval: 5-90 seconds (typically 20-40 seconds)"
  • "Movement: Big toe extension, ankle dorsiflexion, knee/hip flexion"
  • Occurrence in clusters

Sleep Architecture Changes:

• Prolonged sleep latency (> 30 minutes common)
• Reduced sleep efficiency (less than 85%)
• Increased wake after sleep onset
• Normal or increased slow-wave sleep
• Variable REM changes

Ferritin Testing: Critical Nuances

The relationship between ferritin and RLS deserves emphasis:

Standard Laboratory vs RLS-Specific Interpretation: [4,7]

Transferrin Saturation (TSAT):

• Target: > 20%
• If ferritin normal but TSAT less than 20%: functional iron deficiency → treat with iron
• Combined low ferritin + low TSAT: strong indication for iron therapy

When to Refer for Specialist Investigation

---

8. Management

Management of RLS follows a stepwise approach: identify and treat secondary causes, optimise iron status, implement non-pharmacological measures, and use pharmacotherapy when necessary based on symptom frequency and severity.

Management Algorithm

RLS Diagnosis Confirmed
         ↓
Comprehensive Assessment
(Severity, frequency, impact, secondary causes)
         ↓
Check Ferritin & Iron Studies
         ↓
Ferritin less than 75-100 μg/L → IRON SUPPLEMENTATION
         ↓
Review and Stop Exacerbating Medications
(Antihistamines, antidepressants, antiemetics, antipsychotics)
         ↓
Implement Non-Pharmacological Measures
         ↓
    ┌────┴────────────┐
    ↓                 ↓
INTERMITTENT      CHRONIC-PERSISTENT
(less than 2 nights/week)   (≥2 nights/week)
    ↓                 ↓
PRN medication   Assess Severity
as needed            ↓
                ┌────┴────┐
                ↓         ↓
            MILD-MOD   SEVERE
                ↓         ↓
        GABAPENTINOIDS  GABAPENTINOIDS
        (α2δ ligands)   + consider
        FIRST-LINE [5]  combination if
                        inadequate
                ↓
        If refractory → Specialist referral
                → Combination therapy
                → Low-dose opioids
                → Dopamine agonist (aware of augmentation risk) [6]

Non-Pharmacological Management

All patients should receive counselling on lifestyle and behavioural strategies:

Iron Supplementation

Iron therapy is FIRST-LINE treatment in ALL patients with ferritin less than 75 μg/L. [4,7]

Oral Iron Therapy

Optimising Oral Iron Absorption:

• ✅ Take on empty stomach (1 hour before or 2 hours after meals) if tolerated
• ✅ Co-administer with vitamin C (200 mg) to enhance absorption
• ❌ Avoid with: tea, coffee, calcium supplements, PPIs, H2-blockers (reduce absorption)
• ❌ Space from levothyroxine, bisphosphonates (interaction)

Monitoring Oral Iron:

• Check ferritin and TSAT after 3 months of supplementation
• Continue until ferritin > 75-100 μg/L AND TSAT > 20%
• Symptom improvement may lag behind ferritin increase (weeks to months)
• If ferritin not increasing: assess compliance, malabsorption, ongoing losses, consider IV iron

Side Effects:

• Gastrointestinal: nausea (20%), constipation (20%), abdominal discomfort, dark stools (benign)
• Strategies: take with small amount of food, alternate-day dosing, switch formulations, reduce dose

Intravenous Iron Therapy

Indications for IV Iron: [4,13]

• Oral iron intolerance or contraindication
• Malabsorption (inflammatory bowel disease, coeliac disease, post-bariatric surgery)
• Chronic kidney disease (especially if on erythropoiesis-stimulating agents)
• Failure to respond to oral iron after 3-6 months
• Need for rapid repletion in severe symptomatic RLS

Evidence: RCTs demonstrate IV iron (ferric carboxymaltose 500-1000 mg) improves RLS symptoms more effectively than placebo and oral iron, especially when ferritin less than 75 μg/L. [4,13]

Monitoring IV Iron:

• Check ferritin 4-6 weeks post-infusion (allows equilibration)
• Beware over-supplementation: ferritin > 300 μg/L rarely needed and may cause iron overload
• TSAT > 45% suggests iron overload risk

Risks:

• Hypersensitivity reactions (rare but serious with iron dextran)
• Hypophosphataemia (with ferric carboxymaltose; usually transient)
• Infusion reactions (flushing, hypotension)

First-Line Pharmacotherapy: α2δ Calcium Channel Ligands (Gabapentinoids)

Current guidelines recommend α2δ ligands (gabapentin, pregabalin) as first-line pharmacotherapy for chronic-persistent RLS requiring daily medication. [5]

Pregabalin (Preferred)

Evidence: RCTs demonstrate pregabalin 150-450 mg/day significantly reduces RLS symptoms vs placebo, with sustained benefit and no augmentation over 1 year. [14]

Gabapentin

Dosing Schedule Example:

• 1200 mg total daily: 300 mg at 4 PM + 600 mg at 8 PM + 300 mg at bedtime
• Timing is critical: dose 1-2 hours before typical symptom onset

Gabapentin Enacarbil

Evidence: RCTs show 600-1200 mg at 5 PM reduces RLS symptoms vs placebo, sustained over 1 year. [15]

α2δ Ligand: Practical Considerations

Side Effects:

Contraindications/Cautions:

• Renal impairment: dose reduction required (eliminated renally)
• Elderly: start lower doses (increased fall risk, cognitive effects)
• Pregnancy: Category C; limited data
• Avoid abrupt discontinuation (taper to prevent withdrawal)

Why α2δ Ligands Are Preferred Over Dopamine Agonists:

• ✅ No augmentation (major advantage)
• ✅ Effective for pain (common RLS comorbidity)
• ✅ Improve sleep quality
• ✅ Effective for anxiety (common comorbidity)
• ✅ No impulse control disorders
• ❌ More side effects (sedation, weight gain)
• ❌ Slower onset of action than dopamine agonists

Second-Line Pharmacotherapy: Dopamine Agonists

Dopamine agonists are NO LONGER first-line due to augmentation risk but remain effective for selected patients. [6]

Augmentation: The Major Complication

Augmentation is a paradoxical worsening of RLS symptoms with long-term dopaminergic therapy. [6]

Prevalence: 20-60% of patients on long-term dopamine agonists (higher with higher doses, longer duration)

Clinical Features:

1. Earlier onset of symptoms (e.g., symptoms that started at 10 PM now start at 6 PM)
2. Shorter latency to symptoms at rest (symptoms start within minutes of sitting)
3. Shorter duration of medication effect (medication relief lasts less than 6 hours instead of all night)
4. Increased symptom intensity
5. Spread to previously unaffected body parts (arms, trunk)

Risk Factors for Augmentation:

• Higher doses of dopamine agonist
• Longer duration of treatment (risk increases with years)
• Low serum ferritin
• Earlier age of RLS onset

Management of Augmentation:

1. Ensure iron replete (ferritin > 75 μg/L; augmentation less likely with adequate iron) [7]
2. Reduce dopamine agonist dose (if mild augmentation)
3. Switch to α2δ ligand (gabapentin/pregabalin) - preferred strategy
4. Switch to different dopamine agonist (e.g., rotigotine patch) - temporary measure
5. Add α2δ ligand and taper dopamine agonist (combination bridging strategy)
6. Drug holiday (stop dopamine agonist with temporary alternative; challenging)

Specific Dopamine Agonists

Pramipexole

Ropinirole

Rotigotine Transdermal Patch

Dopamine Agonist: Side Effects and Monitoring

Common Side Effects:

• warn all patients |

Serious Side Effects (Require Monitoring):

When to Use Dopamine Agonists Despite Risks:

• Patient preference after informed consent regarding augmentation
• Contraindication to α2δ ligands (severe renal impairment)
• Inadequate response to α2δ ligands
• Intermittent RLS (lower augmentation risk with intermittent use)
• Keep dose LOW (pramipexole ≤0.5 mg, ropinirole ≤2 mg) to minimise augmentation

Refractory RLS and Advanced Therapies

For patients failing standard therapies, specialist referral is recommended.

Low-Dose Opioids

Evidence: Systematic reviews and RCTs demonstrate efficacy of low-dose opioids in refractory RLS. [17]

Indications:

• Severe RLS refractory to α2δ ligands and dopamine agonists
• Severe augmentation from dopamine agonists
• Specialist supervision recommended

Risks:

• Dependency and addiction potential (use lowest effective dose)
• Respiratory depression (avoid in sleep apnoea unless treated)
• Constipation (co-prescribe laxatives)
• Sedation, falls (especially elderly)
• Regulatory restrictions in many countries

Combination Therapy

Combining medications from different classes can be effective:

Effective Combinations:

• α2δ ligand + low-dose dopamine agonist
• α2δ ligand + low-dose opioid
• Low-dose dopamine agonist + low-dose opioid (specialist use)

Rationale: Different mechanisms of action; allows lower doses of each (reduced side effects)

Other Therapies (Limited Evidence)

Special Populations

Pregnancy

Prevalence: 20-30% of pregnant women, especially third trimester [9]

Management:

1. Reassure: Usually resolves within 4 weeks postpartum
2. Non-pharmacological measures: First-line (massage, stretching, moderate exercise)
3. Iron and folate supplementation: Check ferritin; supplement if less than 75 μg/L (most pregnant women are deficient)
4. Avoid pharmacotherapy if possible: Most RLS medications lack safety data in pregnancy
5. If severe and non-responsive:
   • Clonazepam (Category C; short-term use)
   • Opioids (Category C; short-term use; avoid near delivery)
   • α2δ ligands and dopamine agonists generally avoided (limited safety data)

Chronic Kidney Disease and Dialysis

Prevalence: 20-60% in Stage 4-5 CKD and dialysis patients [10]

Pathophysiology: Uraemic toxins, iron deficiency, dialysis-related factors, anaemia, neuropathy

Management:

1. Optimise dialysis adequacy: Increase dialysis time/frequency if suboptimal
2. Iron supplementation: Usually IV iron (oral poorly absorbed in CKD); target ferritin > 200 μg/L in dialysis (higher than non-CKD RLS)
3. Correct anaemia: Ensure haemoglobin 100-120 g/L
4. Gabapentin: First-line pharmacotherapy; dose reduction essential (eliminated renally)
   • CrCl 30-60: 50-75% of usual dose
   • CrCl 15-30: 25-50% of usual dose
   • CrCl less than 15/dialysis: 100-300 mg post-dialysis
5. Avoid dopamine agonists if possible: Increased side effects in CKD
6. Consider kidney transplant: RLS often improves post-transplant

Elderly Patients

Considerations:

• Higher prevalence with age
• More comorbidities (polypharmacy, medication-induced RLS)
• Greater sensitivity to side effects (falls, cognitive impairment)
• Often on RLS-exacerbating medications (antidepressants, antiemetics)

Management:

• Start medications at lower doses
• Slow titration
• Monitor closely for falls, cognitive effects
• Review and minimise polypharmacy

Children and Adolescents

Challenges:

• Diagnostic difficulty (inability to articulate symptoms)
• Often misdiagnosed as "growing pains" or ADHD
• Limited evidence for pharmacotherapy

Management:

• Iron supplementation if ferritin less than 50 μg/L (consider if less than 75 μg/L)
• Non-pharmacological measures emphasised
• Pharmacotherapy reserved for severe cases (specialist supervision)
• Clonidine, gabapentin, clonazepam used off-label (limited evidence)
• Avoid dopamine agonists in children if possible

Intermittent RLS Management

For patients with infrequent symptoms (less than 2 nights/week):

PRN (As-Needed) Strategies:

---

9. Complications and Prognosis

Complications of RLS

Treatment-Related Complications

Prognosis and Natural History

Primary (Idiopathic) RLS

Course:

• Chronic and often progressive over decades
• Not life-threatening but significantly impacts quality of life
• Early onset (less than 45 years): Slower progression; lifelong but may have periods of remission
• Late onset (> 45 years): Faster progression; fewer remission periods

Progression Patterns:

• Gradual increase in symptom frequency (from intermittent to daily)
• Increase in symptom severity
• Extension of circadian window (earlier onset during day)
• May spread to arms (20% of patients)

Spontaneous Remission:

• Uncommon in primary RLS
• May occur in early-onset RLS (remission periods of months to years)
• Pregnancy-related RLS usually resolves postpartum

Secondary RLS

Prognosis depends on underlying cause:

Factors Affecting Prognosis

Long-Term Outcomes

With Appropriate Treatment:

• 70-90% of patients achieve good symptom control [5]
• Quality of life significantly improves
• Sleep normalises
• Mood improves

Challenges:

• Treatment is symptomatic, not curative
• Lifelong management usually required
• Augmentation complicates long-term dopaminergic therapy
• Need for dose escalation over time common

Emerging Therapies and Future Directions:

• Novel iron formulations and delivery methods
• Glutamate antagonists (under investigation)
• Better understanding of genetic mechanisms
• Personalised medicine based on genetic profiles

---

10. Guidelines and Evidence Summary

Major Guidelines

Evidence Summary by Intervention

Iron Supplementation

Evidence Level: HIGH (Level I-II)

Key Studies:

• Oral iron: RCTs show benefit when ferritin less than 75 μg/L; NNT ~5 for significant improvement [4]
• IV iron: RCTs of ferric carboxymaltose (1000 mg) vs placebo show significant symptom reduction at 12 weeks (NNT ~3-4) [4,13]
• Mechanism: Correction of brain iron deficiency improves dopaminergic function

Strength of Recommendation: STRONG for ferritin less than 75 μg/L

α2δ Ligands (Gabapentinoids)

Evidence Level: HIGH (Level I)

Key Studies:

• Pregabalin: Multiple RCTs (150-450 mg/day) show superiority vs placebo; NNT 4-7; sustained benefit at 1 year; no augmentation [14]
• Gabapentin enacarbil: RCTs (600-1200 mg) show efficacy vs placebo; FDA-approved; sustained 1-year benefit [15]
• Gabapentin: Fewer RCTs but clinical evidence supports efficacy; 900-2400 mg/day

Comparison to Dopamine Agonists:

• Similar short-term efficacy
• No augmentation (major advantage) [6]
• Better for comorbid pain, anxiety
• More side effects (sedation, weight gain)

Strength of Recommendation: STRONG as first-line for daily therapy

Dopamine Agonists

Evidence Level: HIGH (Level I) for efficacy; HIGH (Level I) for augmentation risk

Key Studies:

• Pramipexole, ropinirole, rotigotine: Multiple RCTs show efficacy vs placebo; NNT 3-5
• Augmentation: Long-term studies show 20-60% augmentation rate; higher with higher doses [6]
• Guidelines shift: Previously first-line; now second-line due to augmentation

Strength of Recommendation: CONDITIONAL - second-line; use lowest effective dose; monitor for augmentation

Opioids

Evidence Level: MODERATE (Level II)

Key Studies:

• Oxycodone-naloxone: RCT showed efficacy in refractory RLS; prolonged-release formulation [17]
• Other opioids: Observational data; expert consensus

Strength of Recommendation: CONDITIONAL - for refractory RLS; specialist supervision

Evidence Gaps and Controversies

Ongoing Debates:

1. Optimal ferritin threshold: 75 vs 100 μg/L? Guidelines vary.
2. IV vs oral iron: When to use IV? Cost-effectiveness?
3. Cardiovascular risk: Is RLS independently associated with CVD or confounding?
4. Pathophysiology: Exact mechanisms remain incompletely understood
5. Paediatric treatment: Limited evidence for pharmacotherapy
6. Genetic testing: Not currently clinically useful; may become relevant with personalised medicine

---

11. Key Examination and Viva Points

Opening Statement (Viva/OSCE)

"Restless legs syndrome, also known as Willis-Ekbom disease, is a common sensorimotor neurological disorder affecting 5-10% of the population. It is characterised by an irresistible urge to move the legs with uncomfortable sensations, worse at rest and in the evening, relieved by movement. The condition significantly impacts quality of life through sleep disruption and is associated with iron deficiency and dopaminergic dysfunction."

High-Yield Facts for Exams

Must-Know Numbers:

• Prevalence: 5-10% general population [2]
• Female:Male ratio: 2:1
• Positive family history: 40-60% of cases [3]
• PLMs in RLS: 80-90% [12]
• Augmentation risk (long-term dopamine agonists): 20-60% [6]
• Ferritin target: > 75-100 μg/L [4,7]
• RLS in pregnancy: 20-30% (third trimester) [9]
• RLS in dialysis: 20-60% [10]

Must-Know Diagnostic Criteria (IRLSSG 2014) [1]: All 5 required:

1. Urge to move legs ± unpleasant sensations
2. Begins/worsens with rest/inactivity
3. Relieved by movement
4. Worse evening/night (circadian pattern)
5. Not solely due to another condition

Must-Know Pathophysiology:

• Brain iron deficiency → reduced tyrosine hydroxylase → ↓ dopamine synthesis [7]
• A11 diencephalospinal dopaminergic pathway dysfunction [11]
• Genetic loci: BTBD9, MEIS1 (19 total loci identified) [3]

Must-Know Treatment Algorithm:

1. Iron supplementation if ferritin less than 75 μg/L [4]
2. α2δ ligands (gabapentinoids) - first-line daily pharmacotherapy [5]
3. Dopamine agonists - second-line (augmentation risk) [6]
4. Opioids - refractory cases [17]

Must-Know Complications:

• Augmentation: Earlier onset, spread to arms, shorter medication effect [6]
• Impulse control disorders: Dopamine agonists (gambling, shopping, hypersexuality) [16]
• Sleep disruption: Chronic insomnia in > 90% [2]
• Quality of life: Impairment equivalent to T2DM and depression [2]

Common Examiner Questions and Model Answers

Q1: "What are the diagnostic criteria for RLS?"

A: "The International RLS Study Group established five essential criteria in 2014, all of which must be present. First, an urge to move the legs, usually with uncomfortable sensations. Second, symptoms begin or worsen during rest or inactivity. Third, symptoms are partially or completely relieved by movement. Fourth, symptoms are worse in the evening or night than during the day, demonstrating a circadian pattern. Fifth, the symptoms are not solely accounted for by another condition such as leg cramps or positional discomfort."

Q2: "How would you investigate a patient with suspected RLS?"

A: "RLS is primarily a clinical diagnosis based on the five diagnostic criteria. However, investigations are essential to identify secondary causes and guide treatment. First-line blood tests include serum ferritin and transferrin saturation - critical because even 'normal' ferritin between 15-75 μg/L can be insufficient in RLS, and we target ferritin above 75-100 μg/L. I would also check full blood count, renal function including eGFR to exclude chronic kidney disease which affects 20-60% of dialysis patients, blood glucose or HbA1c to exclude diabetes and peripheral neuropathy, and thyroid function. Additional investigations depend on clinical features - nerve conduction studies if peripheral neuropathy is suspected, or polysomnography if there's diagnostic uncertainty, which would show periodic limb movements in 80-90% of RLS patients."

Q3: "What is augmentation and how would you manage it?"

A: "Augmentation is a paradoxical worsening of RLS symptoms that occurs in 20-60% of patients on long-term dopaminergic therapy, particularly dopamine agonists. Clinically, it manifests as earlier onset of symptoms during the day, shorter latency to symptoms when at rest, shorter duration of medication effect, increased symptom intensity, and spread to previously unaffected areas like the arms. Management involves ensuring the patient is iron replete with ferritin above 75 μg/L, as low iron increases augmentation risk. The preferred strategy is switching from the dopamine agonist to an alpha-2-delta ligand such as pregabalin or gabapentin, which do not cause augmentation. This may be done by tapering the dopamine agonist while simultaneously introducing the gabapentinoid, or in severe cases, a brief course of low-dose opioid may be used to bridge the transition."

Q4: "Why is iron important in RLS and how would you treat iron deficiency?"

A: "Iron is essential because it's a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Brain iron deficiency can occur even when serum ferritin is in the 'normal' laboratory range of 15-75 μg/L. Studies using MRI and autopsy have demonstrated reduced brain iron in RLS patients, particularly in the substantia nigra and putamen. For treatment, if ferritin is below 75 μg/L, I would recommend iron supplementation, typically with oral ferrous sulfate 325mg daily or on alternate days, taken on an empty stomach with vitamin C to enhance absorption. It's important to recheck ferritin after 3 months and continue until it's above 75-100 μg/L with transferrin saturation above 20%. If there's intolerance to oral iron, malabsorption, or failure to respond after 3-6 months, intravenous iron such as ferric carboxymaltose should be considered. Randomised trials have shown IV iron is effective even in non-anaemic patients with ferritin below 75 μg/L."

Q5: "What is the first-line pharmacotherapy for RLS and why?"

A: "Current guidelines recommend alpha-2-delta calcium channel ligands, specifically gabapentinoids like pregabalin or gabapentin, as first-line pharmacotherapy for chronic-persistent RLS requiring daily medication. This represents a shift from previous guidelines that favoured dopamine agonists. The key advantage is that gabapentinoids do not cause augmentation, which is a major limitation of dopamine agonists affecting 20-60% of patients long-term. Additionally, gabapentinoids are effective for comorbid conditions common in RLS such as chronic pain, anxiety, and insomnia. Pregabalin is typically started at 75mg one to two hours before symptom onset, usually around 6-8 PM, and titrated to 150-300mg based on response. The main disadvantages compared to dopamine agonists are more side effects including sedation, dizziness, and weight gain, and a slower onset of action."

Common Mistakes to Avoid

❌ Missing ferritin testing - Always check ferritin; don't rely only on Hb ❌ Accepting "normal" ferritin - Target is > 75-100 μg/L, not lab "normal" > 15 μg/L ❌ Starting dopamine agonist first-line - Guidelines now favour gabapentinoids ❌ Using high-dose dopamine agonists - Keep low to minimise augmentation (pramipexole ≤0.5mg) ❌ Not screening for impulse control disorders - Ask about gambling, shopping, hypersexuality with dopamine agonists ❌ Diagnosing RLS without circadian pattern - Evening/night worsening is ESSENTIAL criterion ❌ Forgetting medication review - Antihistamines, SSRIs, antiemetics commonly exacerbate RLS ❌ Not recognising augmentation - Earlier onset and arm spread are red flags ❌ Using benzodiazepines as primary treatment - They improve sleep but don't treat RLS ❌ Levodopa for chronic RLS - High augmentation risk; only for intermittent use

---

12. Patient / Layperson Explanation

What is Restless Legs Syndrome?

Restless legs syndrome (RLS) is a condition where you feel uncomfortable sensations deep in your legs (not on the skin), along with an irresistible urge to move them. The symptoms are worse when you're sitting still or lying down, especially in the evening and at night, and moving your legs makes them feel better temporarily.

People describe the sensations in different ways: "creepy-crawly," "itchy bones," "like worms under the skin," "electric," or "pulling." The key feature is that you have to move your legs to get relief - you might pace, stretch, or rub your legs.

How Common Is It?

RLS affects about 1 in 10 adults, making it one of the more common neurological conditions. It's more common in women than men and can run in families.

What Causes It?

We don't completely understand all the causes, but several factors are involved:

1. Low iron levels - Even if you're not anaemic, low iron stores in the brain can cause RLS. This is the most treatable cause.

2. Brain chemistry - There's a problem with how your brain uses a chemical called dopamine, which helps control movement and sensations.

3. Genetics - It runs in families, suggesting inherited factors.

4. Other conditions - RLS can be triggered by kidney disease, pregnancy, diabetes (through nerve damage), and some medications.

What Makes It Worse?

• Sitting still for long periods (flights, cinema, long meetings)
• Evening and nighttime (symptoms are often worst around bedtime)
• Certain medications: Over-the-counter sleep aids with antihistamines, some antidepressants, anti-sickness tablets
• Caffeine and alcohol
• Lack of sleep (creates a vicious cycle)
• Stress

How Is It Diagnosed?

There's no blood test or scan that diagnoses RLS. Your doctor diagnoses it based on your description of symptoms. However, blood tests are important to check your iron levels and kidney function, as these can cause or worsen RLS.

Your doctor will ask if you have:

1. An urge to move your legs with uncomfortable sensations
2. Symptoms that start or get worse when resting
3. Relief when you move
4. Symptoms worse in the evening/night than during the day
5. Symptoms not explained by another condition

How Is It Treated?

Treatment follows steps:

1. Iron Supplementation (if levels are low)

• Blood tests check your ferritin (iron stores)
• Even "normal" levels may be too low for RLS - your doctor aims for levels above 75-100
• Iron tablets or sometimes iron infusions (through a drip)
• This can take 3-6 months to work but may completely resolve symptoms

2. Lifestyle Changes

• Moderate regular exercise (but not too close to bedtime)
• Avoid caffeine after midday
• Avoid alcohol
• Leg massage and stretching before bed
• Good sleep routine
• Mental activities when symptoms start (puzzles, reading)

3. Medication Review

• Stop or change medications that worsen RLS (with your doctor's guidance)
• Common culprits: antihistamine sleep aids, some antidepressants

4. Prescription Medications (if symptoms are frequent and severe)

• Gabapentin or pregabalin (first choice for daily medication)

  • Taken 1-2 hours before symptoms usually start
  • Help with sleep and any pain
  • "Side effects: drowsiness, dizziness, weight gain"

• Dopamine agonists (pramipexole, ropinirole, rotigotine patch)

  • Work quickly and effectively
  • BUT: long-term use can make RLS worse (called "augmentation")
  • Need careful monitoring
  • Can cause compulsive behaviours (gambling, shopping) - rare but important

• Other medications for severe cases

  • Low-dose pain medications
  • Usually prescribed by specialists

What Is Augmentation?

This is an important complication of dopamine medications (like pramipexole or ropinirole). After months or years of use, the medication can paradoxically make RLS worse:

• Symptoms start earlier in the day
• Symptoms spread to your arms
• Medication doesn't work as long

If this happens, your doctor will usually switch you to a different medication.

Will It Go Away?

This depends on the cause:

It often improves or resolves if caused by:

• Low iron (once iron is corrected)
• Pregnancy (usually goes away within a month after delivery)
• Certain medications (stops when medication is stopped)

It's usually lifelong if it's:

• Primary/genetic RLS (runs in families)
• However, symptoms can be very well controlled with treatment

Living with RLS

What You Can Do:

• Take iron supplements if prescribed (even if you feel they're not working immediately - give it 3-6 months)
• Avoid triggers (caffeine, alcohol, sleep deprivation)
• Plan ahead for situations where you'll need to sit still (flights, theatre) - take PRN medication if prescribed
• Stay physically active
• Inform your doctor about sleep quality and how symptoms affect your daily life

What to Avoid:

• Over-the-counter sleep aids containing antihistamines (diphenhydramine/Benadryl, doxylamine) - these make RLS worse
• Excessive caffeine (limit to morning only)
• Starting new medications without checking if they affect RLS

When to See Your Doctor:

• Symptoms are getting worse despite treatment
• Medication side effects are troublesome
• Developing new symptoms (earlier onset, spreading to arms) - may indicate augmentation
• Significant impact on your quality of life, sleep, or mood

Impact on Quality of Life

RLS can significantly affect your life:

• Difficulty falling asleep and staying asleep
• Daytime tiredness and difficulty concentrating
• Frustration and mood changes
• Avoiding activities that require sitting still
• Relationship strain (partner's sleep disturbed, separate bedrooms)

It's important to communicate with your doctor about how RLS affects you. There are effective treatments available, and many people achieve good control of symptoms.

---

13. References

1. Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria - history, rationale, description, and significance. Sleep Med. 2014;15(8):860-873. doi:10.1016/j.sleep.2014.03.025

2. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165(11):1286-1292. doi:10.1001/archinte.165.11.1286

3. Schormair B, Zhao C, Bell S, et al. Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. Lancet Neurol. 2017;16(11):898-907. doi:10.1016/S1474-4422(17)30327-7

4. Wang J, O'Reilly B, Venkataraman R, Mysliwiec V, Mysliwiec A. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study. Sleep Med. 2009;10(9):973-975. doi:10.1016/j.sleep.2008.11.003

5. Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1-11. doi:10.1016/j.sleep.2016.01.017

6. Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(7):675-684. doi:10.1016/j.sleep.2013.05.016

7. Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology. 2000;54(8):1698-1700. doi:10.1212/wnl.54.8.1698

8. Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res. 2008;43(1):70-75. doi:10.1016/j.jpsychires.2008.02.006

9. Manconi M, Govoni V, De Vito A, et al. Pregnancy as a risk factor for restless legs syndrome. Sleep Med. 2004;5(3):305-308. doi:10.1016/j.sleep.2004.01.013

10. Giannaki CD, Hadjigeorgiou GM, Karatzaferi C, et al. Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review. Kidney Int. 2014;85(6):1275-1282. doi:10.1038/ki.2013.394

11. Clemens S, Rye D, Hochman S. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology. 2006;67(1):125-130. doi:10.1212/01.wnl.0000223316.53428.c9

12. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lespérance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12(1):61-65. doi:10.1002/mds.870120111

13. Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 2011;12(9):906-913. doi:10.1016/j.sleep.2011.05.007

14. Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(24):2585-2593. doi:10.1212/WNL.0000000000003388

15. Kushida CA, Walters AS, Becker P, et al. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology. 2009;72(5):439-446. doi:10.1212/01.wnl.0000341770.91926.cc

16. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589-595. doi:10.1001/archneurol.2010.65

17. Trenkwalder C, Benes H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12(12):1141-1150. doi:10.1016/S1474-4422(13)70239-4

18. Trenkwalder C, Allen R, Högl B, Paulus W, Winkelmann J. Restless legs syndrome associated with major diseases: a systematic review and new concept. Neurology. 2016;86(14):1336-1343. doi:10.1212/WNL.0000000000002542

19. Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG; Medical Advisory Board of the Willis-Ekbom Disease Foundation. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88(9):977-986. doi:10.1016/j.mayocp.2013.06.016

20. Picchietti DL, Bruni O, de Weerd A, et al. Pediatric restless legs syndrome diagnostic criteria: an update by the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(12):1253-1259. doi:10.1016/j.sleep.2013.08.778

21. Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults - an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35(8):1039-1062. doi:10.5665/sleep.1986

22. Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology. 2003;61(3):304-309. doi:10.1212/01.wnl.0000078887.16593.12